To evaluate the pharmacokinetics of SHR7390 in patients with advanced solid tumor.To assess the antitumor activity of SHR7390 combined with SHR-1210 in patients with advanced solid tumors preliminarily and recommend reasonable dosage regimen of SHR7390 for the follow-up clinical trial.